BACKGROUND: Prognosis for most types of childhood tumours has improved during the last few decades. In this article we estimate up-to-date period survival for less common, but important childhood malignancies in Europe. METHODS: Using the database of the Automated Childhood Cancer Information System we calculated period estimates of 10-year survival for the 1995-1999 period for children aged 0-14 years diagnosed during 1985-1999 with tumours of the sympathetic nervous system (NS), retinoblastoma, renal tumours, bone tumours and soft tissue sarcomas in four European regions. RESULTS: Ten-year period survival for 1995-1999 was 66% in children with tumours of the sympathetic NS, 96% for retinoblastoma, 87% for renal tumours, 58% for bone tumours and 61% for soft tissue sarcomas. The higher period estimates, as compared with cohort and complete estimates indicate recent improvement in survival for tumours of the sympathetic NS and to a lesser extent for retinoblastoma and renal tumours. Region-specific period survival estimates were lowest for Eastern Europe for renal, bone and soft tissue tumours, but not for the other two tumour groups. CONCLUSION: There have been further improvements in the 1990s in long-term survival of children diagnosed with several malignancies, albeit to a different extent in different European regions.
BACKGROUND: Prognosis for most types of childhood tumours has improved during the last few decades. In this article we estimate up-to-date period survival for less common, but important childhood malignancies in Europe. METHODS: Using the database of the Automated Childhood Cancer Information System we calculated period estimates of 10-year survival for the 1995-1999 period for children aged 0-14 years diagnosed during 1985-1999 with tumours of the sympathetic nervous system (NS), retinoblastoma, renal tumours, bone tumours and soft tissue sarcomas in four European regions. RESULTS: Ten-year period survival for 1995-1999 was 66% in children with tumours of the sympathetic NS, 96% for retinoblastoma, 87% for renal tumours, 58% for bone tumours and 61% for soft tissue sarcomas. The higher period estimates, as compared with cohort and complete estimates indicate recent improvement in survival for tumours of the sympathetic NS and to a lesser extent for retinoblastoma and renal tumours. Region-specific period survival estimates were lowest for Eastern Europe for renal, bone and soft tissue tumours, but not for the other two tumour groups. CONCLUSION: There have been further improvements in the 1990s in long-term survival of children diagnosed with several malignancies, albeit to a different extent in different European regions.
Authors: Rachel Eyre; Richard G Feltbower; Peter W James; Karen Blakey; Emmanuel Mubwandarikwa; David Forman; Patricia A McKinney; Mark S Pearce; Richard J Q McNally Journal: BMC Cancer Date: 2010-07-06 Impact factor: 4.430
Authors: Deema Hussein; Wiyada Punjaruk; Lisa C D Storer; Lucy Shaw; Ramadhan Othman; Ramadan Ottoman; Andrew Peet; Suzanne Miller; Gagori Bandopadhyay; Rachel Heath; Rajendra Kumari; Karen J Bowman; Paul Braker; Ruman Rahman; George D D Jones; Susan Watson; James Lowe; Ian D Kerr; Richard G Grundy; Beth Coyle Journal: Neuro Oncol Date: 2010-10-25 Impact factor: 12.300
Authors: Jonathan Poels; Gaël Abou-Ghannam; Sophie Herman; Anne Van Langendonckt; François-Xavier Wese; Christine Wyns Journal: Front Surg Date: 2014-12-02
Authors: Ruojin Ren; Weiwei Liu; Li Huang; David Tai Li Liu; Kwong Wai Choy; Jitong Shi; Junyang Zhao; Bowen Zhao; Ming Guan; Carol L Shields; Chi Pui Pang; Bin Li; Gary Hin Fai Yam Journal: Mol Vis Date: 2013-03-15 Impact factor: 2.367
Authors: R Eyre; R G Feltbower; E Mubwandarikwa; H C Jenkinson; S Parkes; J M Birch; T O B Eden; P W James; P A McKinney; M S Pearce; R J Q McNally Journal: Br J Cancer Date: 2009-01-13 Impact factor: 7.640